3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sarcoma
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumors
2
Advanced Endometrial Cancer
2
Thrombosis
1
Thrombophilia
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Resectable Esophageal Squamous Cell Carcinoma
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Nasopharyngeal Neoplasms
1
Multiple Myeloma
1
Metastatic Solid Tumors
1
Melanoma
1
Interventions
Capecitabine
12
Oxaliplatin
10
Radiotherapy
7
Surgical Procedures, Operative
6
Drug Therapy
5
tislelizumab
4
Irinotecan
4
sintilimab
3
Neoadjuvant Therapy
3
Immunotherapy
3
Fluorouracil
3
Endoscopic Mucosal Resection
3
Bevacizumab
3
spartalizumab
2
raltitrexed
2
XELOX
2
Trinitrotoluene
2
Radiation
2
Immune Checkpoint Inhibitors
2
FOLFOXIRI protocol
2
Cetuximab
2
toripalimab
1
sperm releasing substance
1
saxagliptin
1
s-formylglutathione hydrolase
1
envafolimab
1
disitamab vedotin
1
cemiplimab
1
camrelizumab
1
balstilimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Rectal Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled